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Objectives: Tolerance appears to be more easily induced in the fetus before full 
immunocompetence is established, but elucidation of this process is needed. A
model of perinatal tolerance induction to neonatal skin allografts followed by 
cardiac and pulmonary allografts is described. Methods: Sixty Lewis (RT1 I) rat 
fetuses were inoculated intraperitoneally at 18 days' gestation with 1 × 10 7 ACI 
(RT1 a) rat fetal liver cells (group I); 20 Lewis fetuses were inoculated with 2 × 
10 7 ACI fetal liver cells (group H). Control groups consisted of Lewis fetuses 
inoculated with saline solution (n = 25, group HI) and fetuses that were not 
inoculated (n = 25, group IV). Twenty-five of the 50 surviving group I rats 
received ACI skin (<24 hours old) and heart (8 to 10 weeks old) allografts 
(group IA); the remaining 25 rats received only ACI heart grafts (group IB). 
Groups H, IH, and IV received ACI skin and cardiac allografts. Recipients 
tolerant o both skin and cardiac grafts received orthotopic ACI lung grafts 
and third-party skin grafts. Tolerance was indicated by graft survival for more 
than 100 days. Limiting dilution and flow cytometric analyses were performed. 
Results: Abortion rates in groups I, II, HI, and IV were 17% (10/60), 65% 
(13/20), 8% (2/25), and 4% (1/25), respectively. Specific tolerance to skin, 
cardiac, and lung allografts was observed in seven of 25 group IA recipients 
(28%) and seven of seven group H recipients (100%) compared with no 
tolerance in any group IB, HI, or IV recipients (p = 0.03, X 2 test). A 100-fold 
reduction of precursor cytotoxic T lymphocytes and significant splenocyte and 
bone marrow chimerism in tolerant versus nontolerant rats were noted (p = 
0.0001, Student's t test). Conclusions: Using donor-strain fetal liver cells and 
neonatal skin grafts, we achieved higher frequencies of tolerance to solid organ 
grafts in adulthood with lower cell inocula and abortion rates than previously 
described. Chimerism and depressed precursor cytotoxic T lymphocyte fre- 
quencies in tolerant recipients uggest that hematopoietic stem cell engraft- 
ment and clonal deletion/anergy are involved in induction of perinatal toler- 
ance. (J Thorac Cardiovasc Surg 1997;114:64-75) 
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C ongenital defects of the heart and great vessels can be detected in utero as early as the second 
trimester of gestation by means of echocardio- 
graphic imaging. 1 Some of these defects are not 
amenable to conventional postnatal surgical correc- 
tion (e.g., some variants of the hypoplastic left heart 
syndrome and pulmonary atresia with intact ventric- 
ular septum), are associated with high early mortal- 
ity rates, and may require cardiac transplantation i  
the neonatal and pediatric periods for any realistic 
chance for long-term survival. Unfortunately, a sig- 
nificant number of neonates will die awaiting cardiac 
transplantation or shortly after transplantation. 
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Moreover, the side effects of conventional immuno- 
suppression are particularly extreme in the neonatal 
and infant populations. Consequently, research di- 
rected toward developing a means to confer immu- 
nologic tolerance during fetal development in antic- 
ipation of cardiac transplantation has garnered 
interest in recent years. 
Experimental evidence that fetuses are tolerant of 
allogeneic tissue grafts is abundant. In 1953, Billing- 
ham, Brent, and Medawar 2 described the active 
induction of immunologic tolerance in mice by 
exposing the recipient fetus to alloantigen. Recent 
studies in ovine and nonhuman primate models have 
clearly demonstrated that the early gestational fetus 
is tolerant of alloantigens and is an optimal recipient 
of allogeneic hematopoietic stem cells (HSCs). 
HSCs are the pluripotent progenitor cells from 
which key immune cell lines are derived (e.g., lym- 
phocytes, monocytes, granulocytes). Zanjani, 3 Har- 
rison, 4 and their colleagues have successfully intro- 
duced allogeneic HSCs into fetal sheep and rhesus 
monkeys with subsequent multilineage ngraftment 
and without evidence of graft-versus-host disease 
(GVHD).  3'4 However, despite the successful in 
utero induction of low levels of hematopoietic chi- 
merism in sheep, tolerance to subsequent renal 
allografts was not achieved initially. 5 Further tech- 
nical modifications have recently led to in utero 
tolerance induction to postnatal renal allografts. 6 
Nevertheless, the relatively undefined immunologic 
makeup and high cost of these large animal models 
have precluded incisive mechanistic studies of HSC 
engraftment and active tolerance induction in utero. 
To this end, we have developed a relatively inexpen- 
sive, reproducible, and well-characterized rodent 
model of perinatal tolerance induction to skin, 
cardiac, and lung allografts using donor-strain fetal 
liver cells as a source of HSCs. 
Methods 
Animals. Adult timed-pregnant female Lewis (LEW 
and RT11, 8 to 10 weeks old) and ACI (ACI and RT1 a, 8 
to 10 weeks old) rats at 17 days' gestation and adult male 
ACI, LEW, and Brown-Norway (BN, RT1 b, 8 to 10 weeks 
old) rats were obtained from Harlan Sprague Dawley, 
Indianapolis, Indiana. All animals were maintained in the 
animal care facilities of the Department ofCardiothoracic 
Surgery, Stanford University Medical Center, Stanford, 
California. Their environment was maintained at 21 ° -+ 
2 ° C with a time-regulated light period from 7:00 AM to 
7:00 PM. Microisolator-system cages housed three rats per 
cage except in the case of the timed-pregnant ra s, which 
were housed individually. Rats were provided water and 
dry food ad libitum. Periodic serologic analysis of room 
sentinel animals howed that all rats were free of acute 
viral infection. All animals received humane care in 
compliance with the "Principles of Laboratory Animal 
Care," formulated by the National Society for Medical 
Research, and the "Guide for the Care and Use of 
Laboratory Animals," prepared by the National Academy 
of Sciences and published by the National Institutes of 
Health (NIH Publication No. 86-23, revised 1985). 
Fetal liver cell preparation. After being anesthetized 
with sodium pentobarbital (25 mg/kg intraperitoneally) 
and supplemental methoxyflurane (inhalational), timed- 
pregnant ACI rats at 18 days' gestation underwent a 
midline laparotomy with delivery of the bicornuted uterus. 
Each limb of the uterus was incised along its longitudinal 
axis and the fetuses were separated from their placental 
attachments. The fetuses underwent laparotomy with ex- 
trusion and excision of the livers en bloc. The livers were 
immediately placed into phosphate-buffered saline solu- 
tion (PBS) at 4°C and homogenized. The homogenate 
was layered on a Lympholyte-Rat gradient (Accurate 
Chemical & Scientific Corp., Westbury, N.Y.) and centri- 
fuged (1000g at 20 ° to 25°C for 20 minutes). After the 
supernatant layer had been discarded, the interface layer 
containing nucleated fetal liver cells was aspirated and 
placed in a 50 ml conical centrifuge tube and washed three 
times in PBS (400g at 4 ° C for 10 minutes). The fetal liver 
cell suspension concentration was adjusted to obtain 1 × 
107 cells/20 pJ PBS. 
In utero fetal inoculation. With methoxyflurane anes- 
thesia, each timed-pregnant LEW rat at 18 days' gestation 
underwent a midline laparotomy with delivery of the 
bicornuted uterus. Under direct vision aided by transillu- 
ruination, each of 60 LEW fetuses (five litters) were 
inoculated intraperitoneally with 1 × 10 7 ACI fetal liver 
cells (group I) with the use of a Hamilton repeating 
syringe (Hamilton Corp., Reno, N.V.) fitted with a 30- 
gauge needle. Care was taken to avoid tearing the fetal 
tissues with the needle or avulsing the uterine vessels. 
Twenty LEW fetuses (three litters) were similarly inocu- 
lated with 2 × 107 ACI fetal liver cells (group II). For 
controls, each of 25 LEW fetuses (three litters) were 
inoculated with 20 /xl of PBS alone (group III), and 
another 25 LEW fetuses (two litters) received no inocu- 
lations (group IV). 
After the inoculations were completed, the laparotomy 
incisions were closed in two layers with running 4-0 Vicryl 
sutures (Ethicon, Inc., Somerville, N.J.). After recovering 
from anesthesia, the pregnant rats were returned to their 
respective cages and allowed to come to term. 
ACI to LEW neonatal skin transplantation. With the 
aid of deep hypothermia, 4 × 4 mm full-thickness ections 
of neonatal ACI skin were grafted onto 25 of the 50 group 
I LEW neonates that survived to term; this subgroup was 
designated group IA. Group IB consisted of the remaining 
group I neonates, which did not receive skin grafts. All of 
the surviving group II (n = 7), III (n = 23), and IV (n = 
24) LEW neonates received neonatal ACI skin grafts. 
After receiving the grafts, the neonates were slowly re- 
warmed to 37 ° C, returned to their respective maternal 
rats, and permitted to grow and develop normally over the 
next 8 to 10 weeks. No neonates died after skin grafting. 
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Table I. Abortion rates and AC I  allografl tolerance rates among Lewis rats receiving in utero inoculation with 
AC I  fetal liver cells, PBS, and~or no inoculation 
Group (in utero inoculum) No. of fetuses No. of neonates Abortion rate (%) Tolerance rate (%)* 
Group I (1 x 107 fetal cells) 
Group IA--with skin graft 
Group IB--without skin graft 
Group II (2 × 107 fetal cells) 
Group III (PBS) 
Group IV (nothing) 
60 50 17t 28? 
- -  25 - -  28t 
- -  25 - -  0 
20 7 65 100t 
25 23 8 0 
25 24 4 0 
*Tolerance to ACI neonatal skin and/or adult cardiac/lung allografts defined as graft survival more than 100 days. 
tRates ignificantly greater compared with corresponding values in the other groups (p = 0.03; ~2 analysis). 
ACI to LEW heterotopic ardiac transplantation. With 
the animals under sodium pentobarbital (50 mg/kg intra- 
peritoneal) anesthesia, the hearts from adult ACI donor 
rats were transplanted into all mature group IA, IB, II, III, 
and IV LEW rats (8 to 10 weeks old) by means of the 
technique described by Ono and Lindsey. 7
ACI to LEW orthotopic lung transplantation. With the 
aid of sodium pentobarbital (50 mg/kg intraperitoneal) 
and enflurane (1 to 2 volume percent) endotracheal 
anesthesia, left lungs from adult ACI donor rats were 
transplanted orthotopically into all recipients deemed 
tolerant o skin and cardiac allografts (group IA, n = 7; 
group II, n = 7) by means of a modification of the 
technique described by Marck and Wildevuur. 8 
BN to LEW third-party adult skin grafts. With sodium 
pentobarbital (50 mg/kg intraperitoneal) anesthesia, 2 × 2 
cm sections of full-thickness kin, procured from adult 
male BN rats, were grafted onto the flanks of five naive 
LEW adult male rats (controls) and all ACI-tolerant 
group IA and group II LEW recipients (n = 14) 2 weeks 
after lung transplantation. 
Skin, cardiac, and lung allograft evaluation. Neonatal 
ACI skin allografts were evaluated by daily visual inspec- 
tion. Viability was indicated by pigmented (brown) hair 
growth; rejection was indicated by graft sloughing. ACI 
cardiac allografts were assessed by daily abdominal pal- 
pation. Viability was evidenced by strong graft contrac- 
tions; rejection was indicated by the complete absence of 
ventricular contractions. Graft rejection or tolerance was 
confirmed with hematoxylin and eosin histologic analyses 
of myocardial biopsy specimens taken at the time of 
rejection or after 100 days, respectively. Pulmonary grafts 
were graded according to the degree of radiographic 
opacification. Radiographs were subjected to a five-point 
grading scale from 0 to 4 (0 = complete opacification, 4 = 
completely clear lung field). Changes in grades were 
confirmed and correlated with hematoxylin and eosin 
histologic analyses of open lung biopsy specimens. Graft 
rejection was defined as complete radiographic opacifica- 
tion coupled with mononuclear cell infiltration, hemor- 
rhagic vasculitis, or tissue necrosis. Tolerance for all grafts 
was defined as survival in excess of 100 days after trans- 
plantation. Rats in which graft rejection occurred were 
designated "nontolerant." 
Flow cytometric analysis of recipient peripheral blood 
lymphocytes, splenocytes, and bone marrow. Peripheral 
blood lymphocytes (PBLs), splenocytes, and bone marrow 
obtained from all tolerant (after heart and lung transplan- 
tation) and randomly selected nontolerant adult LEW 
recipients (12 to 14 weeks) in groups IA (n = 12; 7 
tolerant, 5nontolerant), IB (n = 5), II (n = 7), III (n = 5), 
and IV (n = 5) were analyzed with flow cytometry 
(FACScan, Becton Dickinson and Company, Rutherford, 
N.J.) to measure the presence of allogeneic (ACI) chimer- 
ism. Naive age-matched LEW (n = 5) and ACI (n = 5) 
rats were used as negative and positive controls, respec- 
tively. 
First, approximately 200 /xl of peripheral blood was 
collected in 10 /xl ethylenediaminetetraacetic ac d by 
means of tail vein puncture from all rats. Second, small 
portions (25%) of splenic tissue were obtained from these 
rats through a 2 cm left subcostal incision performed with 
the rats receiving sodium pentobarbital anesthesia. Fi- 
nally, femoral bone marrow was aspirated from each rat. 
These tissues were collected and homogenized into a 
single-cell suspension in PBS at 4 ° C. For each blood, 
splenocyte, and bone marrow sample, most red cells were 
eliminated in the pellet after sedimentation on a dextran 
gradient. The residual red cells were lysed with ammo- 
nium chloride. Fc receptors were blocked with rat immu- 
noglobulin G or normal rat serum. Cells were stained on 
ice for donor haplotype with fluorescein isothiocyanate- 
conjugated mouse antirat RT1 a monoclonal antibodies 
(PharMingen Research Products, San Diego, Calif.). Cells 
were washed in PBS with a fetal calf serum cushion and 
stained with propidium iodide to exclude dead cells. Flow 
cytometry was used to determine the percentage of donor 
haplotype cells in each animal. Dead cells and debris were 
gated out with forward scatter, orthogonal scatter, and 
propidium iodide staining profiles. Results were expressed 
as the percentage of cells expressing the donor marker 
(RTla). 
Limiting dilution assay for cytotoxic lymphocyte pre- 
cursors. Splenocyte samples were taken from the same 
rats that underwent flow cytometric analysis and were 
assayed for precursor cytotoxic T lymphocyte (CTL) fre- 
quency; samples from within each group were pooled. 
LEW responder cells were plated from 20,000 to 1.28 x 
106 cells per well (24 replicates per concentration) into 
round-bottom icrotiter wells in RPMI 1640 supple- 
mented with 10% fetal bovine serum (HyClone, Logan, 
Utah), 2 mmol/L L-glutamine, 5 × 10 .5 mol/L/3-mercap- 
toethanol, 100 U/ml penicillin, 100 p~g/ml streptomycin, 
20% supernatant from concanavalin A-activated rat 
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Fig. 1. Tolerance to donor-strain (ACI) skin graft. Photo- 
graph displays an ACI skin graft on a tolerant Lewis recip- 
ient after 8 postoperative weeks. Note the pigmented phe- 
notype of the hair produced from the viable ACI skin graft. 
splenocytes, and 50 ~mol/L a-methyl mannoside. Subse- 
quently, 5 × 105 irradiated (2000 rads) ACI stimulator cells 
were added to each well. The plates were incubated in a 
humidified carbon dioxide incubator. After 5 days, aliquots 
from each well were tested for lysis of 5aCt-labeled con- 
canavalin A-activated ACI blasts. Aliquots of supernatant 
were counted in a gamma counter. Wells were considered 
positive if the specific release was greater than 10%. 
Statistical analysis. Tolerance rates observed among 
the different groups were compared by means of 9~ 
analysis. Graft survival times between groups were com- 
pared by means of the Mann-Whitney U test. Chimeric 
levels among the different groups were compared by 
means of the two-tailed Student's t test. Precursor CTL 
frequency was determined by linear regression. 
Results 
Fetal survival/abortions. Abortion rates among 
groups I, II, III, and IV were 17% (10/60), 65% 
(13/20), 8% (2/25), and 4% (1/25), respectively 
Fig. 2. Histologic analysis of ACI cardiac allografts in 
nontolerant and tolerant Lewis recipients. Note the exten- 
sive perivascular and interstitial mononuclear cell infil- 
trates in an ACI cardiac allograft rejected by a Lewis 
recipient on postoperative day 7 (top). No histologic 
evidence of rejection was detected in ACI grafts sampled 
for biopsy 150 days after transplantation in tolerant Lewis 
rats (bottom). (Hematoxylin and eosin stain; original 
magnification × 100.) 
(Table I). The surviving progeny displayed no gross 
anatomic or physiologic abnormalities, including 
evidence of GVHD (e.g., hair loss, failure to thrive, 
diarrhea, or skin lesions), during their maturation. 
Neonatal ACI to LEW skin allograft survival. 
Twenty-eight percent (7/25) of group IA and 100% 
(7/7) of group II LEW recipients of ACI neonatal skin 
allografts clearly displayed pigmented hair growth 
characteristic of the ACI phenotype by postoperative 
day 28, indicating graft viability (Fig. 1). These allo- 
grafts have remained viable for more than 250 days 
without evidence of rejection. In contrast, all of the 
ACI neonatal skin allografts on the remaining nontol- 
erant group IA (18/25; 72%), group III (23/23; 100%), 
and group IV (24/24; 100%) recipients were uniformly 
sloughed off by postoperative day 7, indicating acute 
allograft rejection. 
68 Yuh et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
July 1997 
Fig. 3. Chest radiographs of nontolerant (left) and tolerant (right) lung allograft recipients. The left lung 
field (reversed projection) is opacified in the nontolerant recipient, indicating rejection by postoperative 
day 7, compared with the nearly clear corresponding field in the tolerant animal 100 days after 
transplantation. 
Adult ACI to LEW cardiac allograft survival. All 
group IA and II recipients demonstrating tolerance 
to ACI skin allografts likewise achieved ACI cardiac 
allograft survival times in excess of 200 days to date 
(group IA, n = 7; group II, n = 7), evidenced by 
continued strong graft contractions. Pathologic 
analysis of these grafts revealed no gross or histo- 
logic evidence of rejection (Fig. 2). In the remaining 
nontolerant group IA (n = 18), group IB (n = 25), 
group III (n = 23), and group IV (n = 24) recipi- 
ents, cardiac allograft rejection occurred at 7.0 _+ 
0.3, 6.9 _+ 0.4, 7.1 _+ 0.5, and 6.9 _+ 0.5 days (p = 
0.35), respectively. 
Adult ACI to LEW pulmonary allograft survival. 
All group IA and II recipients demonstrating toler- 
ance to ACI skin and cardiac allografts likewise have 
ACI lung allograft survival times in excess of 100 
days to date (group IA, n = 7; group II, n = 7). 
Allograft tolerance was indicated with serial radio- 
graphs (Fig. 3) and confirmed with pathologic anal- 
ysis of graft tissue (Fig. 4). 
Adult BN to LEW third-party skin allograft sur- 
vival. Third-party Brown-Norway skin graft survival 
times for control (n = 5), tolerant group IA (n = 7), 
and group II (= 7) recipients were 7.0 _+ 1.0, 7.0 _+ 
0.8, and 7.0 _+ 0.0 days, respectively, and were not 
significantly different among the groups (p = 1.00). 
Flow cytometric analysis for PBL, splenocyte, and 
bone marrow allogeneic chimerism. Analysis of the 
PBL populations among all randomly selected ani- 
mals revealed no significant peripheral blood chi- 
merism. However, significant chimerism was de- 
tected in splenocytes (Table II, Fig. 5) from all 
tolerant group IA (1.5% _+ 0.05%,p = 0.0001) and 
group II recipients (1.7% _+ 0.07%, p = 0.0001). 
Generally, higher degrees of chimerism were noted 
in bone marrow populations (Table II, Fig. 6) from 
group IA (55.1% _+ 25.2%,p = 0.0001) and group II 
(60.4% + 23.6%, p = 0.0001). No splenocyte or 
bone marrow chimerism was detected in the nontol- 
erant group IA or group IB recipients, or in the 
group III and IV controls. 
Limiting dilution assay for CTL precursors. 
Limiting dilution analysis revealed a fivefold reduc- 
tion of precursor CTLs in tolerant group IA and II 
graft recipients compared with naive LEW controls 
Co = 0.0001) and a 100-fold reduction compared 
with the nontolerant recipients in groups IA, IB, III, 
and IV (p = 0.0001) (Table III). 
Discussion 
Patients with complex congenital cardiac defects 
that are not amenable to conventional postnatal 
surgical correction are often referred for transplan- 
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tation. Unfortunately, in the neonatal and pediatric 
populations, cardiac transplantation is severely lim- 
ited by organ availability, acute and chronic graft 
rejection, and long-term pharmacologic immuno- 
suppression with its attendant side effects. 9 Nonin- 
vasive prenatal diagnoses of anomalies of the heart 
and great vessels has provided cardiologists and 
cardiac transplant surgeons with a window of oppor- 
tunity during which allogeneic and, possibly, xeno- 
geneic tolerance can be induced during critical 
developmental stages of the immune system. This 
window is indeed narrow, because the human fetal 
immune system becomes competent around the 
fifteenth or sixteenth gestational week and fetal 
safety precludes injections before the thirteenth 
week. 
Reported successes in the treatment of a broad 
spectrum of genetic disorders with postnatal bone 
marrow transplantation has sparked interest in the 
use of pluripotent HSCs to induce allogeneic and 
xenogeneic tolerance in utero. 1° The fetus is an ideal 
host for allogeneic HSC transplantation because of 
its ontogenetic readiness for engraftment and its 
immunodeficient s ate before the sixteenth gesta- 
tional week. During fetal development, the expan- 
sion of the fetal bone marrow compartment and 
HSC distribution patterns may contribute to the 
receptivity of the marrow environment to foreign 
stem cells. In human beings, HSCs are first noted in 
the yolk sac during the fourth week of gestation. 11 
From there, the liver and spleen are seeded uring 
the sixth and seventh weeks, respectively. The bone 
marrow is, in turn, seeded by the liver and assumes 
hematopoietic function by the twentieth week. 
Therefore it follows that the optimal time to inocu- 
late the fetus with donor-derived HSCs might be 
between the thirteenth and sixteenth weeks, before 
immunocompetence is established and before the 
bone marrow is seeded with native HSCs from the 
liver. Furthermore, it has been postulated that do- 
nor HSCs might better compete with native HSCs 
for hematopoietic niches in the marrow if they were 
introduced continuously or repeatedly as opposed to 
a single large dose. A well-defined rodent model of 
in utero allogeneic stem cell engraftment would 
facilitate investigation of these issues. 
Since the initial work reported by Billingham, 
Brent, and Medawar 2in 1953, several rodent models 
of tolerance induction have been designed. Unfor- 
tunately, recent attempts at inducing tolerance in 
utero using rodent models of transplantation have 
met with difficulty in achieving adequate tolerance 
Fig. 4. Histologic analysis of ACI lung allografts in non- 
tolerant and tolerant Lewis recipients. Note he extensive 
perivascular mononuclear cell infiltrates extending into 
the adjacent alveolar septa in an ACI lung allograft 
rejected by a Lewis recipient onpostoperative day 7 (top). 
No histologic evidence of rejection was detected in ACI 
grafts sampled for biopsy 100 days after transplantation in 
tolerant Lewis rats (bottom). (Hematoxylin and eosin 
stain; original magnification ×100.) 
rates for further study. Chen and McCullagh 12 
found that although bone marrow cells administered 
in utero induced tolerance in certain strain combi- 
nations, spleen cells syngeneic with demonstrably 
tolerogenic bone marrow cells not only invariably 
failed to induce tolerance, but commonly resulted in 
sensitized recipients. The inability of the inoculated 
splenocytes tomigrate into the fetal circulation from 
the peritoneal space was excluded as a barrier to 
tolerance induction, because the cells were admin- 
istered intravenously. Kline and colleagues 13were 
successful in achieving tolerance in a semiallogeneic 
rat model of cardiac transplantation by inoculating 
fetal recipients with adult donor-strain splenocytes; 
however, a high cell inoculum (5 × 107 cells/fetus) 
resulting in a high abortion rate (94%) was required 
to induce tolerance. In light of these difficulties, we 
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Table II. Flow cytometric analyses of adult recipient splenocyte and bone marrow populations 
Splenocyte ACI Bone marrow ACI 
(RTU) phenotype (RT1 a) phenotype 
Group* n (mean % + SD) (mean % +_ SD) p Valuet 
ACI positive control (no graft) 5 
Lewis negative control (no graft) 5 
Group IA (tolerant) 7 
Group IA (nontolerant) 5 
Group IB (no skin graft) 5 
Group II (tolerant) 7 
Group III (PBS inoculum in utero) 5 
Group IV (no inoculum in utero) 5 
99.4 -+ 0.05 99.3 + 0.03 - -  
0.2 + 0.03 0.1 -+ 0.04 - -  
1.5 -+ 0.05 55.1 -+ 25.2 0.0001 
0.2 _+ 0.05 0.3 _+ 0.03 1.0000 
0.2 _+ 0.05 0.2 + 0.04 1.0000 
1.7 _+ 0.07 60.4 _+ 23.6 0.0001 
0.3 + 0.08 0.2 -+ 0.03 1.0000 
0.1 -+ 0.02 0.2 +- 0.01 1.0000 
*Group IA--in utero inocuIation with 1 × 107 ACI fetal liver cells; neonatal skin and adult cardiac/lung allografts. 
Group IB~in utero inoculation with 1 × 107 ACI fetal liver cells; adult cardiac allograft only. 
Group II in utero inoculation with 2 × 107 ACI fetal liver cells; neonatal skin and adult cardiac/lung allografts. 
Group III--in utero inoculation with PBS; neonatal skin and adult cardiac allografts. 
Group IV--no in utero inoculation; neonatal skin and adult cardiac allografts. 
tp Values derived from two-tailed Student's t test; all comparisons made with Lewis negative controls. 
developed a more efficient perinatal tolerizing pro- 
tocol using HSCs instead of mature splenocytes. 
In these studies, we demonstrate that tolerance to 
neonatal skin and adult cardiac and lung tissue 
across a strong allogeneic mismatch can be initiated 
by inoculating the recipient fetuses with donor- 
strain fetal liver cells. T cell-depleted fetal liver 
tissue and umbilical cord blood are believed to be 
particularly enriched in HSCs and are tolerogenic 
elements well-suited for in utero administration. 
These elements are relatively easy to obtain and do 
not appear to produce GVHD in the recipient, 
presumably because of a lack of mature competent 
T lymphocytes. By using fetal liver cells instead of 
adult splenocytes as the tolerogen, we achieved a
tolerant state with markedly fewer cells than de- 
scribed by Kline and colleagues. 13 The "immortali- 
ty" of HSCs, not observed with adult splenocytes, 
may be critical for the maintenance of tolerance. In 
fairness, we cannot be certain that the inductive 
elements of the fetal liver inoculum used in our 
model are indeed HSCs, because specific rat HSC 
markers have not yet been identified. However, on 
the basis of experience with fetal liver cells in the 
context of other animal models, 4'14 this appears 
likely. Clinical application of this concept might 
involve the intrauterine administration f fetal liver 
cells or T cell-depleted cord blood to the afflicted 
fetus as opposed to purified HSCs. In fact, HSC 
engraftment may be augmented by a separate "fa- 
cilitator" cell subpopulation 15 that is present in 
whole bone marrow and, quite possibly, fetal liver 
tissue. These facilitator cells might be excluded in 
the process of obtaining a purified HSC inoculum. 
Although we achieved a higher frequency of 
tolerance induction in our model compared with 
other studies, the failure to induce tolerance in 18 of 
25 identically treated rats warrants discussion. It is 
generally believed that HSC engraftment in utero is 
enhanced if such cells are introduced in the early 
stages of gestation and hematolymphoid develop- 
ment; however, the optimal time of inoculation has 
not been defined. It is possible that HSC engraft- 
ment did not occur in nontolerant recipients be- 
cause they were immunocompetent at 18 days' 
gestation. Technical failure in delivering the fetal 
liver cells into the fetal peritoneal space may have 
also accounted for engraftment failure, although 
preliminary trials with dye indicated that our 
method of injection was adequate. Finally, we noted 
that increasing the dose of fetal liver cells increases 
the frequency of tolerance induction, albeit at the 
expense of higher abortion rates. Performing serial 
injections at lower cell doses throughout gestation 
may improve tolerance induction rates while pre- 
serving low rates of abortion. 
Although significantly lower abortion rates were 
observed with this model compared with rates ob- 
served with other rodent models of in utero toler- 
ance induction, we can only speculate as to the 
precise cause of the abortions. We noted no evi- 
dence of GVHD in any surviving animals. Neverthe- 
less, GVHD mediated by mature T cells in the fetal 
liver inoculum may have caused the abortions, al- 
though lymphoid cells isolated from recipient fetal 
livers were nonreactive against donor target cells in 
mixed lymphocyte culture (data not shown). Inter- 
estingly, abortions among similarly inoculated re- 
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cells in utero (tolerant and nontolerant). Note the small subset of splenocytes expressing the donor 
phenotype in the tolerant rat. 
tuses appeared to follow an "all-or-none" pattern; 
entire litters either aborted or were wholly pre- 
served, which suggests that the intrauterine death of 
a few or even a single fetus might be detrimental to 
the entire litter. Mechanical trauma to the fetal 
tissues during inoculation appears to be excluded as 
a significant cause, because a very low abortion rate 
was noted among fetuses inoculated with PBS alone. 
It was not technically feasible to achieve perfectly 
aseptic conditions throughout he cell preparation 
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cells in utero (tolerant and nontolerant). Note the large subset of marrow cells expressing the donor 
phenotype in the tolerant rat. 
and inoculating procedures. Thus it is possible 
that fetal death resulted from infection. Alterna- 
tively, the cellular component of the inoculum 
might be the contributing factor, because the 
abortion rates observed by our group and others 
appear to be proportional to the cell numbers 
used (data not shown). In our studies, doubling 
the cell inoculum from 10 million to 20 million 
cells resulted in a fourfold rise in abortions. 
Whether this phenomenon is a consequence of a 
graft-versus-host effect imparted by competent 
lymphocytes or, perhaps, of metabolic perturba- 
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Table IlL CTL precursor frequencies among adult recipient splenocyte populations 
Group description* n Precursor CTL frequency? p Value$ 
Naive Lewis control (no graft) 5 1,650,000 - -  
Group IA (tolerant) 7 5,700,000 0.0001:~ 
Group IA (nontolerant) 5 55,425 0.0001 
Group IB (no skin graft) 5 52,050 0.0001 
Group II (tolerant) 7 5,500,000 0.0001~: 
Group III (PBS inoculum in utero) 5 70,400 0.0001 
Group IV (no inoculum in utcro) 5 65,550 0.0001 
*Group IA--in utero inoculation with 1 x i0 v ACI fetal liver cells; neonatal skin and adult cardiac/lung allografts. 
Group IB--in utero inoculation with 1 x 107 ACI fetal liver cells; adult cardiac allograft only. 
Group II--in utero inoculation with 2 × 107 ACI fetal liver cells; neonatal skin and adult cardiac/lung allografts. 
Group In-- in utero inoculation with PBS; neonatal skin and adult cardiac allografts. 
Group IV~no in utero inoculation; neonatal skin and adult cardiac allografts. 
tCTL frequencies obtained by linear regression analysis. 
$Statistical comparisons made between each group versus control; comparisons also made between tolerant group IA and II recipients versus groups IA 
(nontolerant), IB, III, and IV. 
tions caused by cell lysis products is presently 
unclear and deserving of further investigation. 
Interestingly, we did not appreciate a uniformly 
significant level of hematopoietic chimerism among 
PBLs from the tolerant rats in early adulthood. Pe- 
ripheral blood chimerism may, in fact, exist in these 
tolerant rats, but at a level that is undetectable byour 
assay. Relatively low but significant levels of chimerism 
were noted among the splenocyte populations. How- 
ever, significantly higher proportions of bone marrow 
cells expressed the donor phenotype. Much has been 
written about the apparent correlation between the 
presence of hematopoietic chimerism and tolerance, 
but few studies have addressed the mechanisms be- 
hind this. One would be hard pressed to logically 
explain how a small subset of chimeric ells would be 
capable of preventing the majority of native lymphoid 
cells from delivering a swift, overwhelming assault 
against an allogeneic solid organ graft. A more palat- 
able hypothesis might propose that chimerism is 
merely a by-product of, rather than the driving force 
behind, tolerance induction. In other words, chimer- 
ism may simply result when donor-strain HSCs, intro- 
duced into the recipient by direct inoculation or the 
transplanted organ itself, are merely permitted to 
survive and proliferate by a recipient immune system 
rendered tolerant by a mechanism that is not based on 
active immunoregulation effected by the HSCs. There- 
fore future studies hould investigate a more passive 
role taken by HSCs in tolerance induction. For in- 
stance, it is widely established that thymic inoculation 
with alloantigen confers tolerance in several models of 
transplantation. 16-as The introduction and subsequent 
engraftment of HSCs in utero would provide a self- 
perpetuating source of alloantigen that might directly 
influence the thymic education process. The durable 
presence of alloantigen may prove to be a key feature 
of future effective tolerance induction regimens. 
We found that, in this model, allogeneic tolerance 
in adult life could be achieved only if donor-strain 
skin was grafted onto the recipient during the 
neonatal period after receiving donor-strain fetal 
liver cells in utero. Furthermore, unlike West, Mor- 
ris, and Wood, 14 we found that the tolerance we 
induced was indeed donor-specific, because third- 
party Brown-Norway adult skin grafts were uni- 
formly rejected among all recipients that were oth- 
erwise tolerant to ACI tissue. These findings, 
coupled with the significantly reduced CTL precur- 
sor frequencies observed in the tolerant recipients 
versus naive animals and nontolerant sensitized 
recipients, suggest that newborn recipients with 
newly engrafted allogeneic HSCs require early con- 
tinuous exposure to corresponding antigenic deter- 
minants during a period of "education" to establish 
allogeneic tolerance. Several investigations have fo- 
cused on the possible mechanisms of this phenom- 
enon and suggested that exposure of the developing 
fetal immune system to donor antigenic determi- 
nants leads to a state of donor-specific unrespon- 
siveness by clonal deletion or anergy. Kappler, 
Roehm, and Marrack 19 demonstrated that clonal 
deletion occurs in utero during the intrathymic 
development of T lymphocytes. Streilein 2° has de- 
scribed clonal anergy whereby reactive T cell clones 
become unresponsive when presented with the ap- 
propriate stimulus. Finally, we have not ruled out 
the induction of a suppressor cell population in 
these studies. 
Although the prenatal induction of allogeneic 
7 4 Yuh et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
July 1997 
tolerance using T cell-depleted bone marrow from 
the solid organ donor might be useful for subse- 
quent pulmonary, renal, or hepatic transplantation 
(e.g., living-related donors), clinical application of in 
utero tolerance induction for cardiac transplanta- 
tion would most likely be realized in a xenogeneic 
context. Successful xenogeneic transplantation of 
human HSCs was initially reported in severe com- 
bined immunodeficient and lethally irradiated nor- 
mal mice. 21' 22 Human-to-sheep and pig-to-monkey 
models of xenogeneic himerism induced from in 
utero transplantation f HSCs have been described 
by Zanjani, 23 Tanaka, 24 and others. However, toler- 
ance to solid organ xenografts has not yet been 
achieved. A basic understanding of the development 
of immunocompetence in utero and the role of 
chimerism in tolerance is needed to establish a 
coherent strategy for perinatal tolerance induction. 
Tolerance induction in the neonatal as opposed to 
the prenatal period would certainly be more condu- 
cive to clinical allogeneic ardiac transplantation. 
West, Morris, and Wood 14 recently reported the use 
of fetal liver cells to induce tolerance to cardiac 
allografts in neonatal mice. Interestingly, they found 
that the induced tolerance was not donor-specific; 
prolongation of third-party allografts, as well as 
donor-type grafts, was observed. This finding en- 
hances the clinical potential of this modality in that 
unmatched fetal liver HSCs might be used. Never- 
theless, we do not believe that it is correct to 
assume, as some investigators have, that the neona- 
tal and fetal immune systems are functionally simi- 
lar. We clearly demonstrate hat untreated neonatal 
rats uniformly and vigorously reject neonatal skin 
allografts despite the grafts being applied within 24 
hours of birth, implying a significant level of immu 
nocompetence in the neonatal period. 
In conclusion, we describe a rodent model of 
perinatal allogeneic tolerance induction. Using fetal 
liver cells and neonatal skin grafts instead of adult 
splenocytes as tolerogens, we achieved a higher 
frequency of tolerance using a markedly lower cell 
inoculum than previously described and incurred 
significantly fewer abortions. Significant levels of 
splenocyte and bone marrow chimerism and a de- 
pressed precursor CTL frequency were noted in 
tolerant recipients. These findings are consistent 
with the hypothesis that the fetal liver contains 
HSCs capable of engraftment in utero. We are 
currently working to identify the specific engrafting 
HSC subsets in fetal liver tissue. This model of 
tolerance induction will be used to determine when 
HSC engraftment occurs after fetal inoculation, 
whether multilineage chimerism develops after HSC 
engraftment, and the optimal timing and dose for 
HSC inoculation. This information should be useful 
in developing techniques used for large animal 
models of in utero allogeneic and xenogeneic toler- 
ance induction and, ideally, in the clinical applica- 
tion of this modality. 
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